Immunotoxins: status and prospects.
Immunotoxins, which are conjugates of cell-binding antibodies and toxins, show considerable promise in the treatment of certain cancers. Genetic engineering is increasingly being used to refine and modify these conjugates, and it is now possible to design, express and purify completely recombinant therapeutic molecules.
Spooner
R A
RA
Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, UK.
Lord
J M
JM
D000818:Animals; D002986:Clinical Trials as Topic; D005818:Genetic Engineering; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000628:therapy
D000922:Immunotoxins